<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477685</url>
  </required_header>
  <id_info>
    <org_study_id>Mediking 0704</org_study_id>
    <secondary_id>OculusGen-2007-04-20</secondary_id>
    <nct_id>NCT00477685</nct_id>
  </id_info>
  <brief_title>Ologen (OculusGen)-Phacotrabeculectomy Historical Control Study in India</brief_title>
  <official_title>Study of the Safety and Effectiveness of the OculusGenTM Collagen Matrix Implant as an Aid in Phacotrabeculectomy Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pro Top &amp; Mediking Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pro Top &amp; Mediking Company Limited</source>
  <brief_summary>
    <textblock>
      1. . Study Objective: The objective of this study is to determine the safety and
           effectiveness of the OculusGenTM Biodegradable Collagen Matrix Implant in
           phacotrabeculectomy surgery. The primary endpoint is to prove the effectiveness via the
           reduction of Intraocular Pressure, and the secondary endpoint is to prove the safety via
           the incidence of complications and adverse events.

        2. . Study Design: The study is designed as a historical controlled study. Patient who meet
           the inclusion/exclusion criteria and sign the informed consent form will be included for
           this study. The allocation of subjects is non-randomized, and there is a single group
           for assignment.

        3. . Follow-Up: This investigation is including 7 post-operative visits and follow-up
           within 6 months from the date of surgery. Patients should be seen at postoperative days
           1, 7, 14, 30, 60, 90 and 180. The visit window of Â± 7 days is allowed for the 30, 60, 90
           and 180 day visits. The further follow-up of subject after trial is continually tracked
           by the investigator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ologen collagen matrix is applied for the phacotrabec surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Preoperative and Postoperative Intraocular Pressure</measure>
    <time_frame>baseline and 90 days</time_frame>
    <description>The preoperative and postoperative intraocular pressure is measured as mmHg at baseline and 90 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Complications or Adverse Events.</measure>
    <time_frame>180 day</time_frame>
    <description>Observation of the incidence of complications, including transient shallow anterior chamber, hyphema, choroidal detachment, hypotony or endophthalmitis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Glaucoma</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>OculusGen Collagen Matrix</arm_group_label>
    <description>OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OculusGen Biodegradable Collagen Matrix Implant</intervention_name>
    <description>OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.</description>
    <arm_group_label>OculusGen Collagen Matrix</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        10
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subject inclusion criteria:

          1. Age 18 years or over.

          2. At least one eye diagnosed with glaucoma and receiving maximally tolerated medical
             therapy.

          3. Visually significant cataract with visual acuity of less than or equal to 6/12.

          4. Subject able and willing to cooperate with investigation plan.

          5. Subject willing to sign informed consent form.

        Subject exclusion criteria:

          1. Known allergic reaction to collagen.

          2. Subject is on Warfarin and discontinuation is not recommended.

          3. Subject with normal tension glaucoma or aphakic glaucoma.

          4. Subject with corneal disease.

          5. Participation in an investigational study during the 30 days proceeding
             phacotrabeculectomy.

          6. Ocular infection within 14 days prior to phacotrabeculectomy.

          7. Pregnant or breast-feeding women.

          8. Monocular subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SPS Grewal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grewal Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grewal Eye Institute</name>
      <address>
        <city>Chandigarh</city>
        <zip>500 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Chen HS, Ritch R, Krupin T, Hsu WC. Control of filtering bleb structure through tissue bioengineering: An animal model. Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5310-4. Erratum in: Invest Ophthalmol Vis Sci. 2007 Feb;48(2):485.</citation>
    <PMID>17122118</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsu WC, Spilker MH, Yannas IV, Rubin PA. Inhibition of conjunctival scarring and contraction by a porous collagen-glycosaminoglycan implant. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2404-11.</citation>
    <PMID>10937547</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2007</study_first_submitted>
  <study_first_submitted_qc>May 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <results_first_submitted>October 24, 2011</results_first_submitted>
  <results_first_submitted_qc>February 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2012</results_first_posted>
  <last_update_submitted>July 1, 2017</last_update_submitted>
  <last_update_submitted_qc>July 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Collagen matrix</keyword>
  <keyword>OculusGen</keyword>
  <keyword>Phacotrabeculectomy</keyword>
  <keyword>anti scarring</keyword>
  <keyword>tissue engineering</keyword>
  <keyword>ologen</keyword>
  <keyword>Aeon Astron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OculusGen Collagen Matrix</title>
          <description>OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OculusGen Collagen Matrix</title>
          <description>OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any Complications or Adverse Events.</title>
        <description>Observation of the incidence of complications, including transient shallow anterior chamber, hyphema, choroidal detachment, hypotony or endophthalmitis.</description>
        <time_frame>180 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OculusGen Collagen Matrix</title>
            <description>OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Complications or Adverse Events.</title>
          <description>Observation of the incidence of complications, including transient shallow anterior chamber, hyphema, choroidal detachment, hypotony or endophthalmitis.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Preoperative and Postoperative Intraocular Pressure</title>
        <description>The preoperative and postoperative intraocular pressure is measured as mmHg at baseline and 90 days.</description>
        <time_frame>baseline and 90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OculusGen Collagen Matrix</title>
            <description>OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Preoperative and Postoperative Intraocular Pressure</title>
          <description>The preoperative and postoperative intraocular pressure is measured as mmHg at baseline and 90 days.</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative intraocular pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="8.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative intraocular pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: the postoperative intraocular pressure at 90 days equals the preoperative intraocular pressure at baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 90 days after surgery.</time_frame>
      <desc>To assess if there was any complications or adverse events, including shallow anterior chamber, hyphema, choroidal detachment, hypotony or endophthalmitis in any patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>OculusGen Collagen Matrix</title>
          <description>OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>S.P.S Grewal, MD</name_or_title>
      <organization>Grewal Eye Institute</organization>
      <phone>+91-172-5056969</phone>
      <email>drgrewal@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

